Fig. 4
From: Pan-urologic cancer genomic subtypes that transcend tissue of origin
Somatic mutations and associated pathways across pan-urologic cancer types and genomic subtypes. a Pathway-centric view of nonsilent gene mutations and copy alterations in urologic cancers (n = 1919 urologic cancer cases with available exome sequencing data), involving key pathways and significantly mutated genes previously implicated in these cancers 5, 6, 10, 52. Panel on the right represents significance of enrichment (one-sided Fisher’s exact test) of gene alteration events for each pathway within any particular genomic subtype/cancer type vs. the rest of the tumors. b For the pathways represented in part a, mutation and copy alteration events involving each gene included in the pathway. For parts a and b, “high-level” deletion and “high-level” amplification respectively approximate total copy loss and copy levels more than 2× greater than that of wild-type (based on GISTIC thresholded values). See also Supplementary Fig. 4 and Supplementary Data 5
